An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors

Jamaji C. Nwanaji-Enwerem, Felicia Fei Lei Chung, Lars Van der Laan, Alexei Novoloaca, Cyrille Cuenin, Harriet Johansson, Bernardo Bonanni, Alan E. Hubbard, Martyn T. Smith, Sheri J. Hartman, Andres Cardenas, Dorothy D. Sears, Zdenko Herceg

Research output: Contribution to journalArticlepeer-review

Abstract

Metformin and weight loss relationships with epigenetic age measures—biological aging biomarkers—remain understudied. We performed a post-hoc analysis of a randomized controlled trial among overweight/obese breast cancer survivors (N = 192) assigned to metformin, placebo, weight loss with metformin, or weight loss with placebo interventions for 6 months. Epigenetic age was correlated with chronological age (r = 0.20–0.86; P < 0.005). However, no significant epigenetic aging associations were observed by intervention arms. Consistent with published reports in non-cancer patients, 6 months of metformin therapy may be inadequate to observe expected epigenetic age deceleration. Longer duration studies are needed to better characterize these relationships. Trial Registration: Registry Name: ClincialTrials.Gov. Registration Number: NCT01302379. Date of Registration: February 2011. URL:https://clinicaltrials.gov/ct2/show/NCT01302379.

Original languageEnglish (US)
Article number224
JournalClinical Epigenetics
Volume13
Issue number1
DOIs
StatePublished - Dec 2021

Keywords

  • Biomarkers
  • DNA methylation age
  • GrimAge
  • PhenoAge
  • RCT

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Developmental Biology
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors'. Together they form a unique fingerprint.

Cite this